For the quarter ending 2025-12-31, OTLK made -$1,207,833 in revenue. -$23,058,135 in net income. Net profit margin of 1909.05%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Revenues, net | -1,207,833 | -30,595.667 | 1,505,322 | |
| Cost of revenues | 29,626 | 305,505 | 439,815 | |
| Gross profit | -1,237,459 | -336,100.667 | 1,065,507 | |
| Research and development | 3,634,352 | 6,681,978 | 7,134,706 | |
| Selling, general and administrative | 8,612,141 | 10,086,250 | 9,679,481 | |
| Loss from operations | -13,483,952 | -17,104,328.667 | -15,748,680 | |
| Loss on equity method investment | -38,634 | -36,707.667 | -30,884 | |
| Interest income | - | 22,434.5 | - | |
| Interest income | 0 | -77,925.667 | -49,351 | |
| Loss from change in fair value of promissory notes | 6,743,736 | 1,250,203 | 2,323,977 | |
| Warrant inducement expenses (note 10) | - | 5,594,457.167 | - | |
| Loss (gain) from change in fair value of warrant liability | 2,791,813 | -15,005,147 | 1,999,610 | |
| Loss before income taxes | - | -14,608,063.333 | -20,152,502 | |
| Income tax (benefit) expense | - | -387,957.25 | - | |
| Net (loss) income | -23,058,135 | -14,090,787 | -20,152,502 | |
| Earnings per share, basic | -0.38 | -0.413 | -0.55 | |
| Earnings per share, diluted | -0.38 | -0.413 | -0.55 | |
| Weighted average number of shares outstanding, basic | 60,205,035 | -720,154 | 36,956,582 | |
| Weighted average number of shares outstanding, diluted | 60,205,035 | -720,154 | 36,956,582 | |
Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc. (OTLK)